183 research outputs found
Recommended from our members
Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration.
We analyzed DCE-MR images from 132 women with locally advanced breast cancer from the I-SPY1 trial to evaluate changes of intra-tumor heterogeneity for augmenting early prediction of pathologic complete response (pCR) and recurrence-free survival (RFS) after neoadjuvant chemotherapy (NAC). Utilizing image registration, voxel-wise changes including tumor deformations and changes in DCE-MRI kinetic features were computed to characterize heterogeneous changes within the tumor. Using five-fold cross-validation, logistic regression and Cox regression were performed to model pCR and RFS, respectively. The extracted imaging features were evaluated in augmenting established predictors, including functional tumor volume (FTV) and histopathologic and demographic factors, using the area under the curve (AUC) and the C-statistic as performance measures. The extracted voxel-wise features were also compared to analogous conventional aggregated features to evaluate the potential advantage of voxel-wise analysis. Voxel-wise features improved prediction of pCR (AUC = 0.78 (±0.03) vs 0.71 (±0.04), p < 0.05 and RFS (C-statistic = 0.76 ( ± 0.05), vs 0.63 ( ± 0.01)), p < 0.05, while models based on analogous aggregate imaging features did not show appreciable performance changes (p > 0.05). Furthermore, all selected voxel-wise features demonstrated significant association with outcome (p < 0.05). Thus, precise measures of voxel-wise changes in tumor heterogeneity extracted from registered DCE-MRI scans can improve early prediction of neoadjuvant treatment outcomes in locally advanced breast cancer
Responsabilità, doveri e coronavirus : l’ossatura dell’ordinamento nelle emergenze “esistenziali"
L\u2019articolo analizza l\u2019emergenza sanitaria determinata dalla diffusione del coronavirus nel prisma delle situazioni giuridiche soggettive, assumendo una prospettiva metodologica basata sui doveri. Lo scopo della ricerca \ue8 di dimostrare che, nelle emergenze \u201cesistenziali\u201d, a differenza di quanto ordinariamente accade in tempi prosperi, i diritti e le libert\ue0 \u2013 pur sempre riconosciuti e tutelati \u2013 arretrano per far spazio ai doveri e alle responsabilit\ue0, al precipuo scopo di assicurare la sopravvivenza dell\u2019ordinamento e degli individui che ne fanno part
ASTHMA AND MAST CELL BIOLOGY
Asthma is a chronic inflammatory disease of the lung and its pathophysiology is initiated by mast cell
activation in response to the antigen binding to IgE receptor as well as by TH2 cell activation. Mast cells
are well established effector cells in asthma where they exacerbate the inflammatory response, playing a
key role in early phase, degranulating and increasing histamine. Human mast cells possess high affinity
IgE receptors and are ubiquitous but predominantly localized in mucosal and connective tissue and are
distributed along blood vessels. There are two types of mast cells: connective tissue mast cells (TC) and
mucosal mast cells (T mast cells). TC mast cells contain more heparin, whereas T mast cells contain
more chondroitin sulfate. In asthma, mast cell activation can trigger degranulation, releasing secretory
granule complex and preformed mediators, such as histamine and proteases, along with the synthesis of
leukotrines and prostaglandins, and induction of cytokines and chemokines. Leukotrine inhibitors and
omalizumab, which inhibits IgE, both relieve the asthma exacerbation when administered to humans
and permit to reduce the use of other drugs. The release of cytokines by mast cells, such as TNF-alpha, IL-1, IL-6 and IL-33, participate in the pathogenesis of asthma. Stress worsens asthma, and this effect
is also mediated by mast cell activation through the release of cytokines. Administration of IL-33 in
experimental animals provokes pathological effects in the mucosal tissues and augments antibody IgE
and IgA in blood vessels. Here, we report the impact of mast cell biology in asthma pathogenesis
Role of apoptosis in wound healing and apoptosis alterations in microgravity
Functioning as the outermost self-renewing protective layer of the human organism, skin protects against a multitude of harmful biological and physical stimuli. Consisting of ectodermal, mesenchymal, and neural crest-derived cell lineages, tissue homeostasis, and signal transduction are finely tuned through the interplay of various pathways. A health problem of astronauts in space is skin deterioration. Until today, wound healing has not been considered as a severe health concern for crew members. This can change with deep space exploration missions and commercial spaceflights together with space tourism. Albeit the molecular process of wound healing is not fully elucidated yet, there have been established significant conceptual gains and new scientific methods. Apoptosis, e.g., programmed cell death, enables orchestrated development and cell removal in wounded or infected tissue. Experimental designs utilizing microgravity allow new insights into the role of apoptosis in wound healing. Furthermore, impaired wound healing in unloading conditions would depict a significant challenge in human-crewed exploration space missions. In this review, we provide an overview of alterations in the behavior of cutaneous cell lineages under microgravity in regard to the impact of apoptosis in wound healing. We discuss the current knowledge about wound healing in space and simulated microgravity with respect to apoptosis and available therapeutic strategies
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study
The association between oxaliplatin and 5-fluorouracil (5-FU) has been extensively reported to improve prognosis of gastric cancer patients. The present study is aimed at evaluating response rate and the toxicity profile of the association with oxaliplatin, 5-FU/lecovorin and epirubicin in gastric cancer patients with locally advanced or metastatic disease. Thirty-six patients have been enrolled and 35 evaluated. The treatment schedule was oxaliplatin (100 mg m−2), 5-FU (400 mg m−2), leucovorin (40 mg m−2) and epirubicin (60 mg m−2) intravenously. administered every 3 weeks for 6 months, for a total of 185 therapy cycles . Response rate and toxicity were assessed according to the international WHO criteria. Every patient received a mean of 5.3 therapy cycles in a day-hospital setting. Sixteen of 35 patients (46%) showed an objective response, two complete response and 14 partial response. Median time to progression was 33 weeks with an overall median survival of 49 weeks. During the study, anaemia grade 3 and neutropenia grade 3 were observed in 9 and 11% of patients respectively. A grade 3 periferic sensorial neuropathy was observed in 6% of patients. No life threatening or cardiac toxicity was recorded. The regimen used showed anticancer activity against gastric carcinoma, a tolerable toxicity profile and excellent patient compliance
- …